2 terminated, 1 active not recruiting, 1 completed, 1 not yet recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Metformin XR: new trials by email Literature Review of Metformin XR trials Research Report on Metformin XR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy Metformin XR, Celecoxib, Valsartan - Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | Myopharm Limited | 48 | 2026-09-01 | 2026-07-08 |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant Alpelisib, Fulvestrant, Metformin XR - Breast Cancer | Phase 2 | Terminated | Novartis Pharmaceuticals | 2 | 2022-04-06 | 2024-10-09 |
| Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction Metformin, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Completed | Wake Forest University Health Sciences | 86 | 2022-01-04 | 2026-06-10 |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Metformin XR, Placebo - Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 60 | 2021-04-27 | 2026-02-09 |
| Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma Metformin XR, Dexamethasone - Multiple Myeloma | Phase 2 | Terminated | University of Campinas, Brazil | 28 | 2017-01-01 | 2026-07-17 |
Breast Neoplasms (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Heart Failure (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hyperglycemia (1) · Inflammation (1) · Monoclonal Gammopathy of Undetermined Significance (1) · Multiple Myeloma (1) · Smoldering Multiple Myeloma (1)
Dana-Farber Cancer Institute (1) · Myopharm Limited (1) · Novartis Pharmaceuticals (1) · University of Campinas, Brazil (1) · Wake Forest University Health Sciences (1)
United States (3) · Australia (1) · Brazil (1) · Malaysia (1)
Catherine R Marinac, PhD (1) · Charles Czank (1) · Dalane W. Kitzman, MD (1) · Omar Nadeem, MD (1)
K22CA251648 (1), U01AG076928 (1)